---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Pharmacokinetics"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Pharmacokinetics. Topics: Absorption, half-life, and clearance after single doses in healthy participants; Dose proportionality; Steady state and accumulation with once-daily dosing; Renal excretion of unchanged drug; 3 further topics. 7 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/pharmacokinetics"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Pharmacokinetics

<a id="heading-2.1.2.6.3"></a>

## 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

### Absorption, half-life, and clearance after single doses in healthy participants

> “Following single oral doses across 5–800 mg, plasma drug concentration–time profiles demonstrated rapid absorption with a median time to maximum concentration (T max) 1.0–1.5 h (Table 3; Figure 1b); the mean terminal half‐life (t 1/2) ranged from 7.9 to 10.5 h, and apparent clearance was comparable, ranging from 18.7 to 27.6 L/h.”
> “The interindividual variability of exposure parameters (C max and AUC0–∞) were low to moderate (<20%).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.6.3-2"></a>

### Dose proportionality

> “Over the dose range of 5–800 mg of lorundrostat in part 1, dose proportional increases in systemic exposure in terms of AUC0–∞ were observed as the 95% CIs of the slopes for the AUCs vs. dose included the value 1.”
> “In contrast, the estimate of the slope (95% CI) for C max versus dose was 1.104 (1.043–1.164), and a slightly greater than dose proportional increase in C max was observed over the range 5–800 mg (Figure S1).”
> “In addition, systemic exposure in terms of the AUC0–24 and C max appeared to increase in a slightly more than dose proportional manner over the tested multiple‐dose range on Days 1 and 7 (Figure S1).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.6.3-3"></a>

### Steady state and accumulation with once-daily dosing

> “A steady state was achieved by approximately Day 5 and very slight accumulation of lorundrostat was observed following multiple dosing compared with Day 1, with the mean rate of accumulation values for AUC0–24 ranging from 1.15 to 1.19 across the entire dose range. Consistent with single‐dose administration, the mean t 1/2 values on Day 7 ranged from 9.1 to 11.9 h.”
> “After single‐ and multiple‐dose lorundrostat administration, plasma levels peaked 1–3 h after administration with a t 1/2 of 10–12 h.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

> “The half-life of lorundrostat (10-12 hours) is ideally suited for once-daily dosing.”
> “Lorundrostat’s observed 10 to 12 hour half-life may be viewed more favorably by physicians compared to compounds with longer half-lives, which may have a greater risk of sustained potassium elevation.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.6.3-4"></a>

### Renal excretion of unchanged drug

> “After a single dose of 40–360 mg of lorundrostat on Day 1, the fraction of the dose excreted in the urine as unchanged was low, with mean values ranging between 1.2%–1.8%. The fraction of the lorundrostat dose excreted remained consistent over the dose range tested. Renal clearance (CLR) was low and generally similar across dose levels (mean CLR ranging between 0.3–0.5 L/h) after a single dose on Day 1.”
> “After 7 days of once‐daily doses of lorundrostat, the fraction of the dose excreted in the urine as unchanged drug was low for all multiple‐dose levels, with mean values ranging between 2.3% and 2.6%.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.6.3-5"></a>

### Food effect

> “Based on the dose escalation data of the first cohort in part 2 where lorundrostat was administered in the fed state, the PK profile did not appear to be affected compared with part 1 where lorundrostat was administered in the fasted state.”
> “Separate from the study we report in this article, a formal food effect study has been conducted and confirms lack of effect of food on the absorption and PK of lorundrostat (tablet formulation; data on file).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.6.3-6"></a>

### Relative exposure of the capsule and tablet formulations

> “The lorundrostat capsule formulation used in the first‐in‐human studies reported here is equivalent to ~50% of exposure seen in the tablet formulation used in the phase II study”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.6.3-7"></a>

### Predicted peak concentration at 100 mg once daily

> “This concentration is 4.8-fold higher than the predicted maximum observed plasma concentration (Cmax) at the maximum clinically efficacious dosage of 100 mg once daily”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="topic-2.1.2.6.3-8"></a>

### Metabolism, protein binding, and volume of distribution

No evidence found.

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
